| Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease NCT05561985 | no aplica | Disponible por acceso ampliado |
| Mielofibrosis NCT04640025 | Fase 2 | Interrumpido |
| Cáncer de pulmón NCT02917993 | Fase 1/2 | Completado |
| GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease NCT03584516 | Fase 2/3 | Interrumpido |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation NCT03978637 | Fase 1/2 | Interrumpido |
| Mielofibrosis, Policitemia vera NCT04629508 | Fase 2 | Completado |
| A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy NCT04071366 | Fase 2 | Completado |
| Linfoma NCT02760485 | Fase 1/2 | Completado |
| Neoplasias hematológicas NCT03320642 | Fase 1 | Interrumpido |
| A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis NCT03144687 | Fase 2 | Completado |
| Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects NCT03721965 | Fase 1/2 | Interrumpido |
| Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects NCT03497273 | Fase 1 | Completado |
| A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis NCT03627052 | Fase 2 | Retirado antes de empezar |
| GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease NCT03139604 | Fase 3 | Completado |
| Tumor sólido NCT02559492 | Fase 1 | Interrumpido |
| Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD NCT02614612 | Fase 1 | Completado |
| Tumor sólido, Cáncer de páncreas NCT01858883 | Fase 1/2 | Completado |
| Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer NCT02257619 | Fase 2 | Interrumpido |
| Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations NCT02355431 | Fase 2 | Retirado antes de empezar |
| An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis NCT01633372 | Fase 2 | Completado |
| Artritis reumatoide NCT01626573 | Fase 2 | Completado |
| Psoriasis en placas NCT01634087 | Fase 2 | Completado |